{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:16:06Z","timestamp":1788369366727,"version":"build-2803163510"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173220"],"award-info":[{"award-number":["82173220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-024-02103-x","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T02:02:18Z","timestamp":1726452138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance"],"prefix":"10.1186","volume":"23","author":[{"given":"Wei","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"3","key":"2103_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2103_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2103_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10333","key":"2103_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328.","journal-title":"Lancet"},{"issue":"2","key":"2103_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Pt 3","key":"2103_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","volume":"86","author":"E Schoutrop","year":"2022","unstructured":"Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022;86(Pt 3):207\u201323.","journal-title":"Semin Cancer Biol"},{"issue":"26","key":"2103_CR7","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"12","key":"2103_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721\u201331.","journal-title":"Lancet Oncol"},{"issue":"25","key":"2103_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"25","key":"2103_CR10","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"2103_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","volume":"166","author":"MM Hardesty","year":"2022","unstructured":"Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022;166(2):219\u201329.","journal-title":"Gynecol Oncol"},{"issue":"23","key":"2103_CR12","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garc\u00eda Y, Banerjee S, Lorusso D, et al. Mirvetuximab Soravtansine in FR\u03b1-Positive, platinum-resistant ovarian Cancer. N Engl J Med. 2023;389(23):2162\u201374.","journal-title":"N Engl J Med"},{"issue":"17suppl","key":"2103_CR13","doi-asserted-by":"publisher","first-page":"LBA5506","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","volume":"41","author":"P Harter","year":"2023","unstructured":"Harter P, Trillsch F, Okamoto A, Reuss A, Kim J-W, Rubio-P\u00e9rez MJ, et al. Durvalumab with paclitaxel\/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1\/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol. 2023;41(17suppl):LBA5506\u2013LBA.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2103_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2103_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN Guidelines\u00ae insights: ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972\u201380.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2103_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41416-021-01460-4","volume":"125","author":"JL Feng","year":"2021","unstructured":"Feng JL, Dixon-Suen SC, Jordan SJ, Webb PM. Statin use and survival among women with ovarian cancer: an Australian national data-linkage study. Br J Cancer. 2021;125(5):766\u201371.","journal-title":"Br J Cancer"},{"issue":"1","key":"2103_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/cr.2014.135","volume":"25","author":"L Ma","year":"2015","unstructured":"Ma L, Li Y, Peng J, Wu D, Zhao X, Cui Y, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015;25(1):24\u201338.","journal-title":"Cell Res"},{"issue":"2","key":"2103_CR18","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404.","journal-title":"J Extracell Vesicles"},{"issue":"14","key":"2103_CR19","doi-asserted-by":"publisher","first-page":"e12144","DOI":"10.1002\/jev2.12144","volume":"10","author":"Y Couch","year":"2021","unstructured":"Couch Y, Buz\u00e0s EI, Di Vizio D, Gho YS, Harrison P, Hill AF, et al. A brief history of nearly EV-erything - the rise and rise of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12144.","journal-title":"J Extracell Vesicles"},{"issue":"10","key":"2103_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","volume":"21","author":"K O\u2019Brien","year":"2020","unstructured":"O\u2019Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21(10):585\u2013606.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2103_CR21","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/med.21918","volume":"42","author":"MD Hade","year":"2022","unstructured":"Hade MD, Suire CN, Mossell J, Suo Z. Extracellular vesicles: emerging frontiers in wound healing. Med Res Rev. 2022;42(6):2102\u201325.","journal-title":"Med Res Rev"},{"issue":"10","key":"2103_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41571-018-0036-9","volume":"15","author":"R Xu","year":"2018","unstructured":"Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018;15(10):617\u201338.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2103_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","volume":"32","author":"W Yu","year":"2021","unstructured":"Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466\u201377.","journal-title":"Ann Oncol"},{"issue":"4","key":"2103_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"7803","key":"2103_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580(7803):381\u20135.","journal-title":"Nature"},{"issue":"4","key":"2103_CR26","doi-asserted-by":"publisher","first-page":"100520","DOI":"10.1016\/j.mcpro.2023.100520","volume":"22","author":"W Zhou","year":"2023","unstructured":"Zhou W, Ma J, Zhao H, Wang Q, Guo X, Chen L, et al. Serum exosomes from epithelial ovarian Cancer patients contain LRP1, which promotes the Migration of Epithelial Ovarian Cancer Cell. Mol Cell Proteom. 2023;22(4):100520.","journal-title":"Mol Cell Proteom"},{"issue":"4","key":"2103_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/cas.12110","volume":"104","author":"X Wang","year":"2013","unstructured":"Wang X, Zhao X, Wang K, Wu L, Duan T. Interaction of monocytes\/macrophages with ovarian cancer cells promotes angiogenesis in vitro. Cancer Sci. 2013;104(4):516\u201323.","journal-title":"Cancer Sci"},{"issue":"16","key":"2103_CR28","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1002\/cam4.3252","volume":"9","author":"X Li","year":"2020","unstructured":"Li X, Tang M. Exosomes released from M2 macrophages transfer mir-221-3p contributed to EOC progression through targeting CDKN1B. Cancer Med. 2020;9(16):5976\u201388.","journal-title":"Cancer Med"},{"issue":"4","key":"2103_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10585-022-10165-8","volume":"39","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Zhu K, Wang G. miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6. Clin Exp Metastasis. 2022;39(4):603\u201321.","journal-title":"Clin Exp Metastasis"},{"issue":"19","key":"2103_CR30","doi-asserted-by":"publisher","first-page":"9183","DOI":"10.1111\/jcmm.16801","volume":"25","author":"J Li","year":"2021","unstructured":"Li J, Hu C, Chao H, Zhang Y, Li Y, Hou J, et al. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma. J Cell Mol Med. 2021;25(19):9183\u201398.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2103_CR31","doi-asserted-by":"publisher","first-page":"e0286017","DOI":"10.1371\/journal.pone.0286017","volume":"18","author":"J Hu","year":"2023","unstructured":"Hu J, Xie C, Xu S, Pu Q, Liu H, Yang L, et al. Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma. PLoS ONE. 2023;18(5):e0286017.","journal-title":"PLoS ONE"},{"issue":"1","key":"2103_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.18632\/aging.202148","volume":"13","author":"L Xing","year":"2020","unstructured":"Xing L, Tang X, Wu K, Huang X, Yi Y, Huan J. LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p. Aging. 2020;13(1):424\u201336.","journal-title":"Aging"},{"issue":"1","key":"2103_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13048-021-00776-2","volume":"14","author":"X Shen","year":"2021","unstructured":"Shen X, Wang C, Zhu H, Wang Y, Wang X, Cheng X, et al. Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells. J Ovarian Res. 2021;14(1):38.","journal-title":"J Ovarian Res"},{"issue":"2","key":"2103_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.bbrc.2005.03.176","volume":"331","author":"Y Kaduka","year":"2005","unstructured":"Kaduka Y, Takeda K, Nakayama M, Kinoshita K, Yagita H, Okumura K. TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage. Biochem Biophys Res Commun. 2005;331(2):384\u201390.","journal-title":"Biochem Biophys Res Commun"},{"key":"2103_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canlet.2017.02.009","volume":"393","author":"Y Hu","year":"2017","unstructured":"Hu Y, Li D, Wu A, Qiu X, Di W, Huang L, et al. TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. Cancer Lett. 2017;393:60\u20137.","journal-title":"Cancer Lett"},{"issue":"5","key":"2103_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","volume":"30","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668\u201381.","journal-title":"Cancer Cell"},{"issue":"1","key":"2103_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2103_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7150\/thno.51777","volume":"11","author":"D Chen","year":"2021","unstructured":"Chen D, Zhang X, Li Z, Zhu B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics. 2021;11(3):1016\u201330.","journal-title":"Theranostics"},{"issue":"2","key":"2103_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/2326-6066.CIR-22-0410","volume":"11","author":"F Wang","year":"2023","unstructured":"Wang F, Niu Y, Chen K, Yuan X, Qin Y, Zheng F, et al. Extracellular vesicle-packaged circATP2B4 mediates M2 macrophage polarization via miR-532-3p\/SREBF1 Axis to promote epithelial ovarian Cancer metastasis. Cancer Immunol Res. 2023;11(2):199\u2013216.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2103_CR40","doi-asserted-by":"publisher","first-page":"e3446","DOI":"10.1002\/jgm.3446","volume":"24","author":"S Yang","year":"2022","unstructured":"Yang S, Zhao H, Xiao W, Shao L, Zhao C, Sun P. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B\/HOXA10 axis. J Gene Med. 2022;24(10):e3446.","journal-title":"J Gene Med"},{"issue":"1","key":"2103_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-022-01703-9","volume":"22","author":"Y Mo","year":"2023","unstructured":"Mo Y, Leung LL, Mak CSL, Wang X, Chan WS, Hui LMN, et al. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Mol Cancer. 2023;22(1):4.","journal-title":"Mol Cancer"},{"key":"2103_CR42","doi-asserted-by":"publisher","first-page":"652322","DOI":"10.3389\/fcell.2021.652322","volume":"9","author":"Y Cui","year":"2021","unstructured":"Cui Y, Wang D, Xie M. Tumor-derived extracellular vesicles promote activation of Carcinoma-Associated fibroblasts and facilitate Invasion and Metastasis of Ovarian Cancer by carrying miR-630. Front Cell Dev Biol. 2021;9:652322.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2103_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","volume":"26","author":"S Pradeep","year":"2014","unstructured":"Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26(1):77\u201391.","journal-title":"Cancer Cell"},{"issue":"5","key":"2103_CR44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302\u201317.","journal-title":"Nat Rev Cancer"},{"key":"2103_CR45","doi-asserted-by":"publisher","first-page":"14470","DOI":"10.1038\/ncomms14470","volume":"8","author":"A Yokoi","year":"2017","unstructured":"Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T, et al. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat Commun. 2017;8:14470.","journal-title":"Nat Commun"},{"key":"2103_CR46","doi-asserted-by":"crossref","unstructured":"Li J, Guo T. Role of peritoneal mesothelial cells in the progression of peritoneal metastases. Cancers (Basel). 2022;14(12).","DOI":"10.3390\/cancers14122856"},{"issue":"1","key":"2103_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13046-021-01899-6","volume":"40","author":"C Wang","year":"2021","unstructured":"Wang C, Wang J, Shen X, Li M, Yue Y, Cheng X, et al. LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1. J Exp Clin Cancer Res. 2021;40(1):101.","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"2103_CR48","doi-asserted-by":"publisher","first-page":"10916","DOI":"10.1111\/jcmm.16983","volume":"25","author":"L Gao","year":"2021","unstructured":"Gao L, Nie X, Gou R, Hu Y, Dong H, Li X, et al. Exosomal ANXA2 derived from ovarian cancer cells regulates epithelial-mesenchymal plasticity of human peritoneal mesothelial cells. J Cell Mol Med. 2021;25(23):10916\u201329.","journal-title":"J Cell Mol Med"},{"key":"2103_CR49","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.omtn.2019.09.032","volume":"18","author":"X Guan","year":"2019","unstructured":"Guan X, Zong ZH, Liu Y, Chen S, Wang LL, Zhao Y. circPUM1 promotes tumorigenesis and progression of ovarian Cancer by sponging mir-615-5p and miR-6753-5p. Mol Ther Nucleic Acids. 2019;18:882\u201392.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"2103_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13402-019-00486-4","volume":"43","author":"X Li","year":"2020","unstructured":"Li X, Tang M, Zhu Q, Wang X, Lin Y, Wang X. The exosomal integrin \u03b15\u03b21\/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration. Cell Oncol (Dordr). 2020;43(2):263\u201377.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2103_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","volume":"15","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, et al. Exosomes promote Ovarian Cancer Cell Invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78\u201392.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2103_CR52","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1186\/s12885-018-4974-5","volume":"18","author":"A Yoshimura","year":"2018","unstructured":"Yoshimura A, Sawada K, Nakamura K, Kinose Y, Nakatsuka E, Kobayashi M, et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065.","journal-title":"BMC Cancer"},{"issue":"11","key":"2103_CR53","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498\u2013503.","journal-title":"Nat Med"},{"issue":"1","key":"2103_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1084\/jem.20181170","volume":"216","author":"W Lee","year":"2019","unstructured":"Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176\u201394.","journal-title":"J Exp Med"},{"issue":"12","key":"2103_CR55","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41419-022-05472-7","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Zeng C, Shu C, Cao Y, Shao W, Zhang M, et al. Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer. Cell Death Dis. 2022;13(12):1028.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2103_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-019-1019-x","volume":"18","author":"JL Hu","year":"2019","unstructured":"Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91.","journal-title":"Mol Cancer"},{"issue":"1","key":"2103_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","volume":"12","author":"T Liu","year":"2019","unstructured":"Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2103_CR58","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/cas.15726","volume":"114","author":"Q Han","year":"2023","unstructured":"Han Q, Tan S, Gong L, Li G, Wu Q, Chen L, et al. Omental cancer-associated fibroblast-derived exosomes with low microRNA-29c-3p promote ovarian cancer peritoneal metastasis. Cancer Sci. 2023;114(5):1929\u201342.","journal-title":"Cancer Sci"},{"key":"2103_CR59","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/OTT.S129502","volume":"10","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Dong W, Wang J, Cai J, Wang Z. Human omental adipose-derived mesenchymal stem cell-conditioned medium alters the proteomic profile of epithelial ovarian cancer cell lines in vitro. Onco Targets Ther. 2017;10:1655\u201363.","journal-title":"Onco Targets Ther"},{"issue":"1\u20132","key":"2103_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11010-013-1746-z","volume":"383","author":"R Lin","year":"2013","unstructured":"Lin R, Wang S, Zhao RC. Exosomes from human adipose-derived mesenchymal stem cells promote migration through wnt signaling pathway in a breast cancer cell model. Mol Cell Biochem. 2013;383(1\u20132):13\u201320.","journal-title":"Mol Cell Biochem"},{"issue":"17","key":"2103_CR61","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1089\/scd.2016.0093","volume":"25","author":"K Takahara","year":"2016","unstructured":"Takahara K, Ii M, Inamoto T, Nakagawa T, Ibuki N, Yoshikawa Y, et al. microRNA-145 mediates the Inhibitory Effect of Adipose tissue-derived stromal cells on prostate Cancer. Stem Cells Dev. 2016;25(17):1290\u20138.","journal-title":"Stem Cells Dev"},{"key":"2103_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cells11213392","volume":"11","author":"Q Qu","year":"2022","unstructured":"Qu Q, Liu L, Cui Y, Chen Y, Wang Y, Wang Y. Exosomes from human omental adipose-derived mesenchymal stem cells secreted into Ascites promote peritoneal metastasis of epithelial ovarian Cancer. Cells. 2022;11:21.","journal-title":"Cells"},{"issue":"1","key":"2103_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10456-018-9645-2","volume":"22","author":"S Li","year":"2019","unstructured":"Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22(1):15\u201336.","journal-title":"Angiogenesis"},{"issue":"1","key":"2103_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF\/VEGFR in Cancer Therapy. Clin Cancer Res. 2023;29(1):30\u20139.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2103_CR65","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248\u201364.","journal-title":"Cell"},{"key":"2103_CR66","doi-asserted-by":"publisher","first-page":"14450","DOI":"10.1038\/ncomms14450","volume":"8","author":"Q Feng","year":"2017","unstructured":"Feng Q, Zhang C, Lum D, Druso JE, Blank B, Wilson KF, et al. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun. 2017;8:14450.","journal-title":"Nat Commun"},{"issue":"1","key":"2103_CR67","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2015.10.011","volume":"370","author":"Y Liu","year":"2016","unstructured":"Liu Y, Luo F, Wang B, Li H, Xu Y, Liu X, et al. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 2016;370(1):125\u201335.","journal-title":"Cancer Lett"},{"key":"2103_CR68","first-page":"899","volume":"18","author":"M Ghorbanian","year":"2019","unstructured":"Ghorbanian M, Babashah S, Ataei F. The effects of ovarian cancer cell-derived exosomes on vascular endothelial growth factor expression in endothelial cells. Excli j. 2019;18:899\u2013907.","journal-title":"Excli j"},{"issue":"26","key":"2103_CR69","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.7150\/thno.37455","volume":"9","author":"L He","year":"2019","unstructured":"He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang J, et al. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 2019;9(26):8206\u201320.","journal-title":"Theranostics"},{"issue":"2","key":"2103_CR70","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12079-020-00548-5","volume":"14","author":"S Masoumi-Dehghi","year":"2020","unstructured":"Masoumi-Dehghi S, Babashah S, Sadeghizadeh M. microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK\/STAT3 and NF-\u03baB signaling pathways. J Cell Commun Signal. 2020;14(2):233\u201344.","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"2103_CR71","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/s41467-018-04695-7","volume":"9","author":"MKS Tang","year":"2018","unstructured":"Tang MKS, Yue PYK, Ip PP, Huang RL, Lai HC, Cheung ANY, et al. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nat Commun. 2018;9(1):2270.","journal-title":"Nat Commun"},{"issue":"5","key":"2103_CR72","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s13402-017-0335-7","volume":"40","author":"K Pakravan","year":"2017","unstructured":"Pakravan K, Babashah S, Sadeghizadeh M, Mowla SJ, Mossahebi-Mohammadi M, Ataei F, et al. MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR\/HIF-1\u03b1\/VEGF signaling axis in breast cancer cells. Cell Oncol (Dordr). 2017;40(5):457\u201370.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2103_CR73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13287-022-02764-9","volume":"13","author":"P Liu","year":"2022","unstructured":"Liu P, Zhang Q, Mi J, Wang S, Xu Q, Zhuang D, et al. Exosomes derived from stem cells of human deciduous exfoliated teeth inhibit angiogenesis in vivo and in vitro via the transfer of mir-100-5p and miR-1246. Stem Cell Res Ther. 2022;13(1):89.","journal-title":"Stem Cell Res Ther"},{"issue":"14","key":"2103_CR74","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1080\/15384101.2019.1624112","volume":"18","author":"T Li","year":"2019","unstructured":"Li T, Li Y, Gan Y, Tian R, Wu Q, Shu G, et al. Methylation-mediated repression of MiR-424\/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23. Cell Cycle. 2019;18(14):1601\u201318.","journal-title":"Cell Cycle"},{"issue":"1","key":"2103_CR75","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12967-020-02652-x","volume":"19","author":"P Li","year":"2021","unstructured":"Li P, Xin H, Lu L. Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting MYB. J Transl Med. 2021;19(1):4.","journal-title":"J Transl Med"},{"issue":"26","key":"2103_CR76","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019;37(26):2317\u201328.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2103_CR77","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928\u201336.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2103_CR78","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2103_CR79","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/2326-6066.CIR-15-0086","volume":"3","author":"RJ Kelleher Jr","year":"2015","unstructured":"Kelleher RJ Jr., Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, et al. Extracellular vesicles Present in Human ovarian tumor microenvironments induce a phosphatidylserine-dependent arrest in the T-cell Signaling Cascade. Cancer Immunol Res. 2015;3(11):1269\u201378.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2103_CR80","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","volume":"10","author":"M Czystowska-Kuzmicz","year":"2019","unstructured":"Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):3000.","journal-title":"Nat Commun"},{"issue":"1","key":"2103_CR81","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12935-021-02018-3","volume":"21","author":"L Yin","year":"2021","unstructured":"Yin L, Wang Y. Long non-coding RNA NEAT1 facilitates the growth, migration, and invasion of ovarian cancer cells via the let-7\u00a0g\/MEST\/ATGL axis. Cancer Cell Int. 2021;21(1):437.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"2103_CR82","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00262-022-03305-2","volume":"72","author":"L Yin","year":"2023","unstructured":"Yin L, Wang Y. Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1\/miR-101-3p\/ZEB1\/PD-L1 axis. Cancer Immunol Immunother. 2023;72(3):743\u201358.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2103_CR83","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/2326-6066.CIR-22-0426","volume":"11","author":"DC Hinshaw","year":"2023","unstructured":"Hinshaw DC, Benavides GA, Metge BJ, Swain CA, Kammerud SC, Alsheikh HA, et al. Hedgehog signaling regulates Treg to Th17 Conversion through metabolic rewiring in breast Cancer. Cancer Immunol Res. 2023;11(5):687\u2013702.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2103_CR84","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/2326-6066.CIR-17-0479","volume":"6","author":"J Zhou","year":"2018","unstructured":"Zhou J, Li X, Wu X, Zhang T, Zhu Q, Wang X, et al. Exosomes released from Tumor-Associated macrophages transfer miRNAs that induce a Treg\/Th17 Cell Imbalance in Epithelial Ovarian Cancer. Cancer Immunol Res. 2018;6(12):1578\u201392.","journal-title":"Cancer Immunol Res"},{"issue":"35","key":"2103_CR85","doi-asserted-by":"publisher","first-page":"e2303835","DOI":"10.1002\/adma.202303835","volume":"35","author":"L Tang","year":"2023","unstructured":"Tang L, Yin Y, Cao Y, Fu C, Liu H, Feng J, et al. Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based Cancer Immunotherapy. Adv Mater. 2023;35(35):e2303835.","journal-title":"Adv Mater"},{"issue":"9","key":"2103_CR86","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/1541-7786.MCR-20-0956","volume":"19","author":"A Shimizu","year":"2021","unstructured":"Shimizu A, Sawada K, Kobayashi M, Yamamoto M, Yagi T, Kinose Y, et al. Exosomal CD47 plays an essential role in Immune Evasion in Ovarian Cancer. Mol Cancer Res. 2021;19(9):1583\u201395.","journal-title":"Mol Cancer Res"},{"key":"2103_CR87","doi-asserted-by":"publisher","first-page":"1087689","DOI":"10.3389\/fimmu.2022.1087689","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Zhou Y, Zhang J, Zhang Y, Long S, Lin X, et al. NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions. Front Immunol. 2022;13:1087689.","journal-title":"Front Immunol"},{"issue":"3","key":"2103_CR88","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2103_CR89","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41419-021-03490-5","volume":"12","author":"J Cai","year":"2021","unstructured":"Cai J, Gong L, Li G, Guo J, Yi X, Wang Z. Exosomes in ovarian cancer ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. Cell Death Dis. 2021;12(2):210.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2103_CR90","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-021-01463-y","volume":"20","author":"C Li","year":"2021","unstructured":"Li C, Teixeira AF, Zhu HJ, Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021;20(1):154.","journal-title":"Mol Cancer"},{"issue":"1","key":"2103_CR91","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10985549.2022.2160605","volume":"43","author":"X Chen","year":"2023","unstructured":"Chen X, Ren X, Zhou EJ, Bian Y. Exosome-transmitted circIFNGR2 modulates ovarian Cancer metastasis via miR-378\/ST5 Axis. Mol Cell Biol. 2023;43(1):22\u201342.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2103_CR92","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41467-023-37403-1","volume":"14","author":"H Shin","year":"2023","unstructured":"Shin H, Choi BH, Shim O, Kim J, Park Y, Cho SK, et al. Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers. Nat Commun. 2023;14(1):1644.","journal-title":"Nat Commun"},{"issue":"1","key":"2103_CR93","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-024-02997-x","volume":"43","author":"D de Miguel-Perez","year":"2024","unstructured":"de Miguel-Perez D, Ak M, Mamindla P, Russo A, Zenkin S, Ak N, et al. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. J Experimental Clin Cancer Research: CR. 2024;43(1):81.","journal-title":"J Experimental Clin Cancer Research: CR"},{"issue":"7","key":"2103_CR94","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/neuonc\/noae068","volume":"26","author":"FL Ricklefs","year":"2024","unstructured":"Ricklefs FL, Wollmann K, Salviano-Silva A, Drexler R, Maire CL, Kaul MG, et al. Circulating extracellular vesicles as biomarker for diagnosis, prognosis, and monitoring in glioblastoma patients. Neuro Oncol. 2024;26(7):1280\u201391.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2103_CR95","doi-asserted-by":"publisher","first-page":"1789326","DOI":"10.1080\/20013078.2020.1789326","volume":"9","author":"K Burbidge","year":"2020","unstructured":"Burbidge K, Zwikelmaier V, Cook B, Long MM, Balva B, Lonigro M, et al. Cargo and cell-specific differences in extracellular vesicle populations identified by multiplexed immunofluorescent analysis. J Extracell Vesicles. 2020;9(1):1789326.","journal-title":"J Extracell Vesicles"},{"key":"2103_CR96","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canlet.2019.10.038","volume":"469","author":"CC Eylem","year":"2020","unstructured":"Eylem CC, Yilmaz M, Derkus B, Nemutlu E, Camci CB, Yilmaz E, et al. Untargeted multi-omic analysis of colorectal cancer-specific exosomes reveals joint pathways of colorectal cancer in both clinical samples and cell culture. Cancer Lett. 2020;469:186\u201394.","journal-title":"Cancer Lett"},{"key":"2103_CR97","doi-asserted-by":"crossref","unstructured":"Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N et al. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024;42(7).","DOI":"10.1016\/j.ccell.2024.06.003"},{"key":"2103_CR98","doi-asserted-by":"crossref","unstructured":"Shen L, Huang H, Wei Z, Chen W, Li J, Yao Y et al. Integrated transcriptomics, proteomics, and functional analysis to characterize the tissue-specific small extracellular vesicle network of breast cancer. MedComm (2020). 2023;4(6):e433.","DOI":"10.1002\/mco2.433"},{"issue":"2","key":"2103_CR99","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41592-023-02117-1","volume":"21","author":"R He","year":"2024","unstructured":"He R, Zhu J, Ji P, Zhao F. SEVtras delineates small extracellular vesicles at droplet resolution from single-cell transcriptomes. Nat Methods. 2024;21(2):259\u201366.","journal-title":"Nat Methods"},{"key":"2103_CR100","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semcancer.2020.12.024","volume":"77","author":"A Ghoneum","year":"2021","unstructured":"Ghoneum A, Almousa S, Warren B, Abdulfattah AY, Shu J, Abouelfadl H, et al. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Semin Cancer Biol. 2021;77:83\u201398.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"2103_CR101","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, et al. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(12):1731\u20138.","journal-title":"JAMA Oncol"},{"issue":"9","key":"2103_CR102","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","volume":"19","author":"CY Lan","year":"2018","unstructured":"Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239\u201346.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2103_CR103","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/annonc\/mdq357","volume":"22","author":"JJ Biagi","year":"2011","unstructured":"Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials Group Study. Ann Oncol. 2011;22(2):335\u201340.","journal-title":"Ann Oncol"},{"issue":"2","key":"2103_CR104","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","volume":"19","author":"JM Lee","year":"2018","unstructured":"Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018;19(2):207\u201315.","journal-title":"Lancet Oncol"},{"issue":"15suppl","key":"2103_CR105","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1200\/JCO.2016.34.15_suppl.5547","volume":"34","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Oza AM, Secord AA, Roman LD, Blagden SP, Banerjee SN, et al. Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): results of a randomized phase II study. J Clin Oncol. 2016;34(15suppl):5547.","journal-title":"J Clin Oncol"},{"issue":"15suppl","key":"2103_CR106","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1200\/JCO.2019.37.15_suppl.5518","volume":"37","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Cabanero M, Cristea MC, Mantia-Smaldone G, Olawaiye A, Ellard S, et al. A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: a trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia. J Clin Oncol. 2019;37(15suppl):5518.","journal-title":"J Clin Oncol"},{"key":"2103_CR107","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.canlet.2016.12.017","volume":"388","author":"P Todeschini","year":"2017","unstructured":"Todeschini P, Salviato E, Paracchini L, Ferracin M, Petrillo M, Zanotti L, et al. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts. Cancer Lett. 2017;388:320\u20137.","journal-title":"Cancer Lett"},{"key":"2103_CR108","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ebiom.2018.11.004","volume":"38","author":"P Kanlikilicer","year":"2018","unstructured":"Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, et al. Exosomal miRNA confers chemo resistance via targeting Cav1\/p-gp\/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018;38:100\u201312.","journal-title":"EBioMedicine"},{"issue":"5","key":"2103_CR109","first-page":"2124","volume":"11","author":"T Li","year":"2021","unstructured":"Li T, Lin L, Liu Q, Gao W, Chen L, Sha C, et al. Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer. Am J Cancer Res. 2021;11(5):2124\u201341.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2103_CR110","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2014.12.042","volume":"137","author":"RC Pink","year":"2015","unstructured":"Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DR. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143\u201351.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"2103_CR111","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/cbin.11671","volume":"45","author":"L Zhuang","year":"2021","unstructured":"Zhuang L, Zhang B, Liu X, Lin L, Wang L, Hong Z, et al. Exosomal mir-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1. Cell Biol Int. 2021;45(10):2140\u20139.","journal-title":"Cell Biol Int"},{"issue":"1","key":"2103_CR112","doi-asserted-by":"publisher","first-page":"e2202642","DOI":"10.1002\/advs.202202642","volume":"10","author":"C Wu","year":"2022","unstructured":"Wu C, Liu Y, Liu W, Zou T, Lu S, Zhu C, et al. NNMT-DNMT1 Axis is essential for maintaining Cancer Cell sensitivity to oxidative phosphorylation inhibition. Adv Sci (Weinh). 2022;10(1):e2202642.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"2103_CR113","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/cbf.3276","volume":"35","author":"YL Cao","year":"2017","unstructured":"Cao YL, Zhuang T, Xing BH, Li N, Li Q. Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer. Cell Biochem Funct. 2017;35(6):296\u2013303.","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"2103_CR114","doi-asserted-by":"publisher","first-page":"13924","DOI":"10.1038\/s41598-019-50436-1","volume":"9","author":"M Asare-Werehene","year":"2019","unstructured":"Asare-Werehene M, Communal L, Carmona E, Le T, Provencher D, Mes-Masson AM, et al. Pre-operative circulating plasma Gelsolin predicts residual Disease and detects early stage ovarian Cancer. Sci Rep. 2019;9(1):13924.","journal-title":"Sci Rep"},{"issue":"7","key":"2103_CR115","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41388-019-1087-9","volume":"39","author":"M Asare-Werehene","year":"2020","unstructured":"Asare-Werehene M, Nakka K, Reunov A, Chiu CT, Lee WT, Abedini MR, et al. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene. 2020;39(7):1600\u201316.","journal-title":"Oncogene"},{"issue":"18","key":"2103_CR116","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1158\/0008-5472.CAN-20-0788","volume":"80","author":"M Asare-Werehene","year":"2020","unstructured":"Asare-Werehene M, Communal L, Carmona E, Han Y, Song YS, Burger D, et al. Plasma Gelsolin inhibits CD8(+) T-cell function and regulates glutathione production to Confer Chemoresistance in Ovarian Cancer. Cancer Res. 2020;80(18):3959\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"2103_CR117","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41698-021-00152-9","volume":"5","author":"D Parashar","year":"2021","unstructured":"Parashar D, Geethadevi A, McAllister D, Ebben J, Peterson FC, Jensen DR, et al. Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L\/CRR9-mediated chemotherapeutic drug resistance. NPJ Precis Oncol. 2021;5(1):16.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"2103_CR118","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13046-015-0145-6","volume":"34","author":"X Zhou","year":"2015","unstructured":"Zhou X, Jin W, Jia H, Yan J, Zhang G. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res. 2015;34(1):28.","journal-title":"J Exp Clin Cancer Res"},{"key":"2103_CR119","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1476-4598-7-35","volume":"7","author":"A Laios","year":"2008","unstructured":"Laios A, O\u2019Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7:35.","journal-title":"Mol Cancer"},{"issue":"1","key":"2103_CR120","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-019-1095-1","volume":"38","author":"X Zhu","year":"2019","unstructured":"Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38(1):81.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2103_CR121","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1021\/acs.molpharmaceut.2c00557","volume":"20","author":"C Chen","year":"2023","unstructured":"Chen C, Zhang L, Ruan Z. GATA3 encapsulated by Tumor-Associated macrophage-derived extracellular vesicles promotes Immune escape and Chemotherapy Resistance of Ovarian Cancer cells by upregulating the CD24\/Siglec-10 Axis. Mol Pharm. 2023;20(2):971\u201386.","journal-title":"Mol Pharm"},{"key":"2103_CR122","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12935-019-1051-3","volume":"19","author":"H Guo","year":"2019","unstructured":"Guo H, Ha C, Dong H, Yang Z, Ma Y, Ding Y. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cancer Cell Int. 2019;19:347.","journal-title":"Cancer Cell Int"},{"key":"2103_CR123","doi-asserted-by":"crossref","unstructured":"Samuel P, Mulcahy LA, Furlong F, McCarthy HO, Brooks SA, Fabbri M et al. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells. Philos Trans R Soc Lond B Biol Sci. 2018;373(1737).","DOI":"10.1098\/rstb.2017.0065"},{"issue":"15","key":"2103_CR124","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"28","key":"2103_CR125","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1038\/s41388-018-0189-0","volume":"37","author":"KDP Dorayappan","year":"2018","unstructured":"Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, et al. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3\/Rab proteins. Oncogene. 2018;37(28):3806\u201321.","journal-title":"Oncogene"},{"issue":"1","key":"2103_CR126","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41420-021-00489-x","volume":"7","author":"L Qian","year":"2021","unstructured":"Qian L, Yang X, Li S, Zhao H, Gao Y, Zhao S, et al. Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer. Cell Death Discov. 2021;7(1):112.","journal-title":"Cell Death Discov"},{"key":"2103_CR127","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.addr.2019.06.008","volume":"143","author":"C Su","year":"2019","unstructured":"Su C, Liu Y, Li R, Wu W, Fawcett JP, Gu J. Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems. Adv Drug Deliv Rev. 2019;143:97\u2013114.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2103_CR128","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8(1):293.","journal-title":"Signal Transduct Target Ther"},{"issue":"51","key":"2103_CR129","doi-asserted-by":"publisher","first-page":"e2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for Cancer Therapy. Adv Mater. 2023;35(51):e2303261.","journal-title":"Adv Mater"},{"issue":"11","key":"2103_CR130","doi-asserted-by":"publisher","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","volume":"16","author":"R Tenchov","year":"2022","unstructured":"Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA. ExosomesNature\u2019s lipid nanoparticles, a rising star in Drug Delivery and Diagnostics. ACS Nano. 2022;16(11):17802\u201346.","journal-title":"ACS Nano"},{"issue":"13","key":"2103_CR131","doi-asserted-by":"publisher","first-page":"16420","DOI":"10.1021\/acsami.2c22749","volume":"15","author":"W Zhang","year":"2023","unstructured":"Zhang W, Ngo L, Tsao SC, Liu D, Wang Y. Engineered Cancer-Derived Small Extracellular vesicle-liposome hybrid delivery system for targeted treatment of breast Cancer. ACS Appl Mater Interfaces. 2023;15(13):16420\u201333.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"2103_CR132","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","volume":"20","author":"L Li","year":"2022","unstructured":"Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20(1):50.","journal-title":"J Nanobiotechnol"},{"key":"2103_CR133","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","volume":"24","author":"B Zhitomirsky","year":"2016","unstructured":"Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 2016;24:23\u201333.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"2103_CR134","doi-asserted-by":"publisher","first-page":"1440132","DOI":"10.1080\/20013078.2018.1440132","volume":"7","author":"M Somiya","year":"2018","unstructured":"Somiya M, Yoshioka Y, Ochiya T. Biocompatibility of highly purified bovine milk-derived extracellular vesicles. J Extracell Vesicles. 2018;7(1):1440132.","journal-title":"J Extracell Vesicles"},{"key":"2103_CR135","doi-asserted-by":"publisher","first-page":"810761","DOI":"10.3389\/fmed.2022.810761","volume":"9","author":"G Zhou","year":"2022","unstructured":"Zhou G, Gu Y, Zhu Z, Zhang H, Liu W, Xu B, et al. Exosome mediated cytosolic cisplatin delivery through clathrin-independent endocytosis and enhanced anti-cancer effect via avoiding endosome trapping in cisplatin-resistant ovarian Cancer. Front Med (Lausanne). 2022;9:810761.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2103_CR136","doi-asserted-by":"publisher","first-page":"1265291","DOI":"10.1080\/20013078.2017.1265291","volume":"6","author":"Z Yuan","year":"2017","unstructured":"Yuan Z, Kolluri KK, Gowers KH, Janes SM. TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy. J Extracell Vesicles. 2017;6(1):1265291.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"2103_CR137","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12967-022-03422-7","volume":"20","author":"X Wang","year":"2022","unstructured":"Wang X, Jiang L, Liu Q. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance. J Transl Med. 2022;20(1):258.","journal-title":"J Transl Med"},{"issue":"1","key":"2103_CR138","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2103_CR139","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3892\/ijmm.2020.4634","volume":"46","author":"L Qiu","year":"2020","unstructured":"Qiu L, Wang J, Chen M, Chen F, Tu W. Exosomal microRNA\u2013146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2\u2013mediated PI3K\/Akt axis. Int J Mol Med. 2020;46(2):609\u201320.","journal-title":"Int J Mol Med"},{"issue":"7","key":"2103_CR140","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/03639045.2020.1776320","volume":"46","author":"X Zhang","year":"2020","unstructured":"Zhang X, Liu L, Tang M, Li H, Guo X, Yang X. The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells. Drug Dev Ind Pharm. 2020;46(7):1150\u201362.","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"2103_CR141","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341\u20135.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2103_CR142","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.annonc.2023.02.004","volume":"34","author":"O Amato","year":"2023","unstructured":"Amato O, Aftimos P, Ignatiadis M. Liquid biopsy accelerates precision medicine. Ann Oncol. 2023;34(4):333\u20135.","journal-title":"Ann Oncol"},{"issue":"2","key":"2103_CR143","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2023.02.044","volume":"165","author":"X Guo","year":"2023","unstructured":"Guo X, Peng Y, Song Q, Wei J, Wang X, Ru Y, et al. A Liquid Biopsy Signature for the early detection of gastric Cancer in patients. Gastroenterology. 2023;165(2):402\u2013e1313.","journal-title":"Gastroenterology"},{"issue":"5","key":"2103_CR144","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/JS9.0000000000000249","volume":"109","author":"X Guo","year":"2023","unstructured":"Guo X, Gao Y, Song Q, Wei J, Wu J, Dong J, et al. Early assessment of circulating exosomal lncRNA-GC1 for monitoring neoadjuvant chemotherapy response in gastric cancer. Int J Surg. 2023;109(5):1094\u2013104.","journal-title":"Int J Surg"},{"issue":"5","key":"2103_CR145","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1053\/j.gastro.2022.06.090","volume":"163","author":"K Nakamura","year":"2022","unstructured":"Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, et al. An exosome-based Transcriptomic Signature for Noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a Multicenter Cohort Study. Gastroenterology. 2022;163(5):1252\u2013e662.","journal-title":"Gastroenterology"},{"issue":"19","key":"2103_CR146","doi-asserted-by":"publisher","first-page":"19197","DOI":"10.1021\/acsnano.3c05694","volume":"17","author":"L Li","year":"2023","unstructured":"Li L, Zhang F, Zhang J, Shi X, Wu H, Chao X, et al. Identifying serum small extracellular vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian Cancer. ACS Nano. 2023;17(19):19197\u2013210.","journal-title":"ACS Nano"},{"key":"2103_CR147","doi-asserted-by":"publisher","first-page":"707658","DOI":"10.3389\/fonc.2021.707658","volume":"11","author":"P Li","year":"2021","unstructured":"Li P, Bai Y, Shan B, Zhang W, Liu Z, Zhu Y, et al. Exploration of potential diagnostic value of protein content in serum small extracellular vesicles for early-stage epithelial ovarian carcinoma. Front Oncol. 2021;11:707658.","journal-title":"Front Oncol"},{"key":"2103_CR148","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","volume":"363","author":"B Tao","year":"2023","unstructured":"Tao B, Du R, Zhang X, Jia B, Gao Y, Zhao Y, et al. Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. J Control Release. 2023;363:692\u2013706.","journal-title":"J Control Release"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-024-02103-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T13:04:53Z","timestamp":1726491893000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-02103-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":148,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1186\/s12943-024-02103-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"201"}}